Abstract: Papillary lesions comprise a wide spectrum of lesions in terms of their clinical presentation, morphologic appearance, malignant potential, and clinical behavior. Their defining feature is that of a fibrovascular stromal core lined by epithelial and myoepithelial cells, attached to the wall of the duct and extending into the duct lumen. Papillary lesions are often diagnostically challenging both on core biopsy and in excision specimens. Much of the difficulty arises from the many different terminologies that are used to describe the various entities that are included under the umbrella term of papillary lesions. Separation of papillary lesions into categories with a meaningful clinical outcome is most appropriate; however, there is a relative paucity of well-designed outcome studies with substantial cohort numbers to provide information in this regard. We use a pragmatic approach to the classification of papillary lesions in our practice, as we will outline in this review. We will also discuss controversies surrounding papillary lesions and focus on management of these lesions on core biopsy and in excision specimens.
CYTOLOGIC FINDINGS
Papillary lesions, both benign and malignant, are a challenging cytologic diagnosis. Benign papillary lesions can be difficult to distinguish from fibroadenomas or fibrocystic change and from low-grade malignant proliferations, often leading to an indeterminate cytologic diagnosis. Broad 3-dimensional branching fragments with ruffled tips and tiny tonguelike projections are characteristic. 1 Distinguishing benign from malignant papillary proliferations is particularly challenging due to their overlapping features and many authors have sought, with varying degrees of success, to find discriminatory features. [1] [2] [3] Studies examining the correlation between fine needle aspiration diagnoses of papillary lesions and histologic findings show mixed results [4] [5] [6] ; most studies report low concordance. Therefore, a definitive benign or malignant diagnosis should only be made with caution when the lesion is identified as being papillary in nature.
INTRADUCTAL PAPILLOMA
Intraductal papillomas are often solitary and central and most commonly occur in the fifth and sixth decades of life. [7] [8] [9] In contrast, multiple papillomas are seen in younger patients and occur far less frequently than solitary papillomas. 10 
Clinical Features
Solitary papillomas are usually located beneath the areola whereas multiple papillomas are often peripherally located. Either location may be associated with the clinical presentation of nipple discharge that may be bloody or clear. Peripheral papillomas are more likely to be clinically occult and are often discovered on mammography as microcalcifications or, less commonly, as masses. Palpable lesions average 2 to 3 cm, but cystic lesions can be larger than 10 cm. 11 Microscopic papillomas may represent incidental findings in biopsies targeting other lesions.
Radiologic Findings
Mammography may show a well-defined mass in the case of a solitary papilloma, whereas multiple papillomas may show nodular masses or microcalcifications. Ultrasonography may be useful in demonstrating a cystic component in cases where a clinically palpable lesion is present. Magnetic resonance imaging is a highly sensitive modality for detecting intraductal papillomas, especially in younger women with dense breasts; however, dynamic and rim enhancement mimicking invasive breast cancer may be seen. 12 Filling defects can be demonstrated by ductography. Ductoscopy is a newer technique that allows endoscopic evaluation of the duct system, permitting cytologic and tissue sampling and possible therapeutic intervention (reviewed in Ref. 13 ).
Microscopic Findings
Arborescent papillae within a dilated duct or ducts are typically seen, although areas with little branching leading to a solid appearance are not infrequent (Fig. 1) . A myoepithelial cell layer is invariably present between the epithelial cells and the basement membrane (Figs. 2A,  B) , although it can be focally absent. Myoepithelial cells can be quite prominent and sometimes hyperplastic and are identified by their more rounded contour and paler cytoplasm. The overlying luminal epithelial cells may be cuboidal or assume a columnar cell configuration; any degree of epithelial hyperplasia of usual type may be seen. Prominent epithelial proliferation may lead to complexity of architecture with fusion of papillary fronds and formation of secondary lumina (Figs. 3A, B) . Not infrequently, apocrine and less commonly, squamous metaplasia can be present, the latter typically at a site of infarction or previous core biopsy. Rarely, clear cell, mucinous, or sebaceous metaplasia are seen. Caution must be observed when assessing atypia within apocrine cells. The criteria for assessing atypia in apocrine cells in the nonpapilloma setting are followed (reviewed in Ref. 14) . An atypical apocrine proliferation that involves adjacent ducts should raise the possibility of DCIS. 15 Sclerosis of the cores, possibly a result of remote ischemic injury, may be seen. 16 This sclerosing process can be extensive and may lead to entrapment of ductal epithelium resulting in a pattern which may be mistaken for invasive carcinoma. The absence of malignant cytology, preservation of a myoepithelial cell layer, and lack of a true desmoplastic response facilitates the diagnosis. Hemorrhagic infarction resulting from torsion of the cores can lead to the clinical presentation of a bloody nipple discharge. Infarction hinders evaluation of atypia or malignancy; however, a diagnosis of papillary carcinoma should not be made unless evidence of malignancy is unequivocal and recognizable in viable tissue. 17 Admixed patterns of sclerosing adenosis and cystic dilatation with a central area of sclerosis can produce a mass resembling a radial scar/complex sclerosing lesion. Occasionally, a thickened duct wall encloses a sclerosing adenosis growth pattern within the duct lumen, a pattern frequently referred to as duct adenoma.
Clinical Significance and Prognostic Implications
Determining the relationship between intraductal papillomas and malignancy is hindered by their frequent coexistence with other proliferative breast lesions, with and without atypia. Multiple papillomas have been shown by 3-dimensional reconstruction studies 18 to be continuous with hyperplastic alterations within adjacent lobular units. Many authors have reported an increased risk of subsequent breast carcinoma when lesions are multiple. 7, 8 But, whether or not atypia was present within these lesions was not a recognized issue at the time that many of these studies were performed. 17 Carter 19 found that 6 of 64 patients with a benign intraductal papilloma developed carcinoma at 5 to 17 years follow-up. The incidence was higher in patients with multiple papillomas and was further elevated by coexisting proliferative disease. Studies from the Nashville benign breast series have shown that the presence of a papilloma, without surrounding proliferative changes, doubles the subsequent breast cancer risk relative to the general population, a level similar to other forms of proliferative breast disease without atypia. 20 The most comprehensive study evaluating the risk of breast cancer associated with benign papillomas has recently been published from the Mayo clinic. 10 This study included 372 solitary papillomas and 41 multiple papillomas. A complex mixture of proliferative changes accompanied the papillomas, with sclerosing adenosis and usual ductal hyperplasia present in at least 50% of cases from each papilloma subgroup. Radial scars occurred at significantly increased frequency compared with patients without papillomas. Patients with a solitary papilloma without atypia had a 2-fold risk of developing breast cancer (compared with a risk of 1.9 for patients with proliferative disease without atypia and lacking a papilloma). Patients with multiple papillomas without atypia had a relative risk of 3. Patients with a papilloma were not significantly more likely to develop an ipsilateral breast cancer as opposed to a contralateral breast cancer when compared with patients with benign breast disease that did not include a papilloma.
In summary, papillomas have been shown to be associated with an increased risk of malignancy, the risk being greater with multiple papillomas than with solitary papillomas. This risk is modified by the presence of accompanying proliferative disease. The risk seems to be bilateral and over a long term, therefore, conservative management with close observation is the current recommended management.
ATYPICAL DUCTAL HYPERPLASIA AND DCIS ARISING IN AN INTRADUCTAL PAPILLOMA

Microscopic Findings
A neoplastic population of cells, warranting the diagnosis of atypical ductal hyperplasia (ADH) or lowgrade DCIS, may be seen within what is otherwise a benign intraductal papilloma (Figs. 4A, B) . These neoplastic components are recognized as a uniform population of cells with round, hyperchromatic nuclei forming a rigid architecture, with absence of cellular streaming and overlapping. We use the criteria of Page et al 21 to differentiate ADH from low-grade DCIS within a papilloma. This determination is based on the extent of the uniform population; ADH is diagnosed if the extent of the atypical population (within the papilloma) is r3 mm; DCIS is diagnosed if the lesion is >3 mm. This 3 mm extent criterion is in contrast to the 2 mm extent criterion we use in the nonpapilloma setting.
It has been suggested by some authorities that the presence of a neoplastic population of cells, regardless of extent, should be considered as in situ papillary carcinoma. 22 Others 17 have used the term ''atypical papilloma'' when less than a third of the papilloma displays these features, and ''carcinoma arising in a papilloma'' when greater than a third but less than 90% of the papilloma shows these changes.
The size 21 or proportion 17 criteria are only applied to low-grade lesions. If higher-grade lesions are present a diagnosis of carcinoma in a papilloma is made regardless of extent. 
Incidence and Clinical Significance of ADH Within a Papilloma
Multiple peripheral papillomas are much more likely to be associated with ADH or DCIS than solitary papillomas, with reports of ADH occurring in up to 43% of cases of multiple peripheral papillomas. 23 Ohuchi et al 24 found that 6 of 16 patients with peripheral papillomas had associated DCIS compared with none of 9 patients with central papillomas. Ali-Fehmi et al 25 found that most patients (80.4%) in their study with multiple papillomas had either coexisting atypical lesions (which included ADH, atypical lobular hyperplasia, and lobular carcinoma in situ), or malignant lesions (DCIS or invasive carcinoma). They observed that while ADH/ atypical lobular hyperplasia were frequently observed in breast sections outside the field of the papillomas, DCIS and invasive carcinomas nearly always arose within multiple papillomas.
In a nested study by Page et al 21 the risk of developing breast cancer in women who had ADH within a papilloma was 7.5 times greater than the risk for women with papillomas without ADH. Patients who also had ADH in the surrounding breast parenchyma had an even higher relative risk. The carcinomas that developed involved the ipsilateral breast in all but one case. In contrast, in a small series of 12 cases of ADH within a papilloma, Raju and Vertes 26 did not find a preponderance of ipsilateral breast cancer development.
Lewis et al, 10 in the Mayo Clinic series, reported the relative risk of breast cancer in patients with solitary and multiple papillomas with atypia (using the criteria by Page et al 21 ) to be 5 and 7-fold, respectively. In addition, in patients with a solitary papilloma with atypia, the location of the atypia (either within or outside the papilloma) did not influence the risk of developing breast cancer. Similar to the findings of Raju and Vertes, 26 patients did not show a significant tendency to ipsilateral breast cancer development. Both of these studies support the concept that atypia associated with a papilloma is a marker of increased risk rather than a precursor lesion.
In summary, multiple definitions as to what constitutes atypia within a papilloma exist. Atypia seems to be more frequently seen in multiple papillomas compared with solitary papillomas. Although one study suggests that ADH within a papilloma behaves as a precursor lesion, most studies would favor its role as a generalized risk factor for the development of breast cancer.
INTRACYSTIC PAPILLARY CARCINOMA
Intracystic papillary carcinoma is a rare entity which is specific enough in its clinical presentation, morphologic appearance, and behavior to warrant distinction between both papillary DCIS and DCIS arising in an intraductal papilloma.
Clinical Features
Intracystic papillary carcinoma accounts for between 1% and 2% of all breast cancers. 27 Patients are typically older than those with solitary intraductal papillomas. Lesions average a few centimeters but can reach up to 10 cm in diameter. A palpable mass is present in up to 90% of patients. 17 Nearly 50% arise centrally and nipple discharge, often blood tinged, occurs in at least a third of patients. 28 
Radiologic Findings
Intracystic papillary carcinomas often appear as rounded, circumscribed mass lesions on mammography. 29, 30 McCulloch et al 31 reported that these lesions frequently appear as a single, ill-defined, and lobulated mass on mammography that rarely show microcalcifications; and as a well-defined, inhomogeneous, and hypoechoic lesion with posterior enhancement on ultrasound. A cystic portion may be identified which can show septation. 32 
Microscopic Findings
The term intracystic papillary carcinoma is reserved for those lesions that typically are solitary and frequently central. They consist of a dilated duct completely occupied by a neoplastic population of cells supported by a papillary scaffolding (Fig. 5) . The hallmark of this lesion is the absence of myoepithelial cells within the intraductal proliferation (Fig. 6) . Various growth patterns have been described. 33 Slender papillae, lined by a single layer of malignant cells, often tall or columnar, lying directly on the stromal core without an intervening myoepithelial cell layer, may be seen (Fig. 7A) . Alternatively, the proliferation may assume a cribriform architecture with rigid, punched-out regular spaces (Fig. 7B) , or a solid growth pattern, studded with fibrovascular cores (Fig. 7C ). Low nuclear grade is typically seen, although higher-grade lesions in addition to tumor cell necrosis may be present. Dimorphic papillary carcinoma is a term that has been used to refer to the appearance of an apparent second population of cells that are polygonal with pale cytoplasm and grow in solid or cribriform nests beneath a superficial layer of malignant columnar cells. 34 These are not to be confused with myoepithelial cells. The nuclear features are similar in both populations, but, immunohistochemical staining confirms their epithelial origin. Unusual morphologic variants such as secretory endometriumlike morphology 35 and tall cell variant of thyroid papillary carcinomalike 36 have been described.
Apocrine metaplasia, although frequently seen in intraductal papillomas, is not a feature of intracystic papillary carcinomas, although malignant apocrine cells may rarely occupy a portion of the neoplastic population. Hemorrhage is often present within the cystic space. The cyst wall is typically thickened and fibrotic. Sclerosis may be marked with resultant disruption of the regular, rounded contour. Entrapment of malignant cells within a sclerotic wall can mimic an invasive process (Fig. 5) .
Myoepithelial Cells and Intracystic Papillary Carcinoma
Although intracystic papillary carcinoma is widely believed to represent an in situ process, the demonstration of myoepithelial cells at the periphery of the cystically dilated duct wall is not a consistent feature (Fig. 8) . Early immunohistochemical studies evaluating the use of myoepithelial cell markers in differentiating between in situ and invasive carcinoma have shown that, typically, the myoepithelial cell layer is scant or lost in these lesions despite the absence of stromal invasion on hematoxylin and eosin examination. 37, 38 Two recent studies have assessed the presence and distribution of myoepithelial cells at the periphery of intracystic papillary carcinomas using a panel of highly sensitive markers that recognize myoepithelial cell components. In 9 cases classified as intracystic papillary carcinoma by Hill and Yeh 39 a myoepithelial cell layer was identified in just 4 cases. The authors proposed the term ''encapsulated papillary carcinoma'' for such lesions that lack myoepithelial cells and suggest that these may represent borderline lesions in a spectrum of progression from in situ to invasive carcinoma.
Collins and colleagues 40 reported that immunohistochemical studies using a panel of 5 different myoepithelial markers in 22 intracystic papillary carcinomas failed to demonstrate a myoepithelial cell layer at the periphery of the nodules in all 22 cases. In contrast, a continuous layer of myoepithelial cells was seen around adjacent foci of conventional DCIS and surrounding all of the benign intraductal papillomas. The authors suggest that the most likely explanation for these findings is that at least a subset, if not all, intracystic papillary carcinomas represent circumscribed nodules of invasive papillary carcinoma rather than purely in situ disease, albeit with a clinically indolent behavior. Given this, the authors state that they support the use of the terminology encapsulated papillary carcinoma as proposed by Hill and Yeh 39 for these lesions. We also support the use of this term in this clinical setting.
Prognosis and Management of Intracystic Papillary Carcinoma
The prognosis for patients with intracystic papillary carcinoma is excellent. Lefkowitz et al 34 reported a 10-year survival rate of 100% and a disease-free survival rate of 91%. Carter et al 41 demonstrated that the presence of DCIS in the breast tissue adjacent to an intracystic papillary carcinoma was associated with an increased risk of recurrence compared with those lesions without adjacent DCIS. They concluded that the latter were more likely to be cured by local treatment. MacGrogan and Tavassoli 42 reported similar findings in their study of 119 central papillomas; the presence or extent of atypia (using the criteria of Tavassoli 17 ) when confined to the papilloma, did not influence recurrence of either benign or malignant papillary lesions.
Metastases rarely occur in patients with intracystic papillary carcinoma. Lefkowitz et al 34 reported the presence of axillary lymph node or distant metastases in 3 patients with in situ papillary carcinomas in their series of 77 patients. A limitation of this study was that only 3 to 4 sections per tumor were sampled in each case; thus, the possibility of stromal invasion in these cases was not adequately excluded. A study of the treatment and outcome of patients with intracystic papillary carcinoma by Solorzano et al 43 identified 2 patients who presented subsequently with metastatic carcinoma in the axilla and bone at 28 months and 7 years, respectively. We recently reported 2 cases of intracystic papillary carcinoma with metastases to sentinel lymph nodes. 44 Both intracystic papillary carcinomas were large; at least 4 cm in maximum dimension. But, despite extensive or in toto sampling, stromal invasion was not identified in either case. In summary, all cases of regional or distant metastases associated with an intracystic papillary carcinoma have been reported as rare case reports confirming that these occurrences are extremely unusual. Most of the patients with intracystic papillary carcinoma have an excellent prognosis. Thus, although we support a change in the terminology of these lesions to encapsulated papillary carcinoma as first proposed by Hill and Yeh, 39 we recommend a conservative approach to their management.
SOLID PAPILLARY CARCINOMA
The term solid papillary carcinoma describes a tumor, usually occurring in older patients, composed of circumscribed nodules of epithelial cells which are typically ovoid or spindle-shaped with low nuclear grade (Fig. 9) . 45 Neuroendocrine features with granular eosinophilic cytoplasm and immunoreactivity for chromogranin are frequently seen. Extracellular and intracellular mucin is a common feature and these tumors are frequently associated with mucinous (colloid) carcinoma, raising the possibility that these lesions represent the preinvasive phase of the cellular variant of mucinous carcinoma. The possibility that solid papillary carcinoma represents an invasive tumor with a pushing margin rather than a pure in situ lesion has been raised. 46 As with intracystic papillary carcinomas immunohistochemical studies have failed to demonstrate a myoepithelial cell layer in most solid papillary carcinomas. 45, 47 That a subset of solid papillary carcinomas may represent a special type of lowgrade ''pushing'' carcinoma may explain the very rare findings of metastases to axillary lymph nodes 46 and distant sites. 45 Nevertheless, solid papillary carcinoma of the breast, even when associated with conventional areas of invasive carcinoma, has been reported to behave indolently. 46 
INTRACYSTIC PAPILLARY CARCINOMA (ENCAPSULATED PAPILLARY CARCINOMA) WITH INVASION
Intracystic papillary carcinoma (encapsulated papillary carcinoma) may be associated with stromal invasion. This can range from a focus of microinvasion to much larger areas of invasion. McCulloch et al 31 found in their study of the radiologic features of papillary carcinomas that those with stromal invasion were larger than those without; although, no other mammographic or sonographic features distinguished invasive from noninvasive tumors.
Microscopic Findings
When invasion is present it is important to note that the invasive component is rarely invasive papillary carcinoma, which is exceedingly rare, but is typically invasive ductal carcinoma, no special type. In making the diagnosis of invasion in this setting, stromal invasion beyond the cyst wall is usually required.
Measuring Extent of Invasion
There are no well-established rules to follow in approaching this issue and common sense must prevail when determining invasive tumor size. For example, in the case of a 4 cm intracystic papillary carcinoma (encapsulated papillary carcinoma) that has an associated unequivocal focus of invasive carcinoma (Fig. 10) ; we would measure the extent of this latter focus (eg, 1.5 mm, in this case) and report this as an ''encapsulated papillary carcinoma with an invasive ductal carcinoma, no special type, 1.5 mm in maximum extent.'' We would communicate to the clinician that the tumor is more appropriately staged on the basis of the 1.5 mm focus of unequivocal invasion (ie, T1a), rather than being staged on the basis of the size of the encapsulated papillary carcinoma. The goal is to prevent overtreatment of such lesions.
INVASIVE PAPILLARY CARCINOMA
Invasive papillary carcinoma is rare, accounting for <2% of breast cancers in most symptomatic series [48] [49] [50] and it may be more frequent in the elderly. 48 The diagnostic feature of invasive papillary carcinoma is an invasive tumor consisting of papillary structures with fibrovascular cores, lined by malignant cells. The papillary structures may be so closely packed as to obscure their underlying papillary nature. 51 Nuclear pleomorphism and mitoses are variable. In a series by Fisher et al 48 mucin secretion was seen in two-thirds of the cases of invasive papillary carcinoma. Pure papillary carcinoma is rare and is most often seen admixed with another special type or a carcinoma of no special type. We reserve the 
EPITHELIAL DISPLACEMENT
Papillary lesions are inherently friable and are particularly prone to epithelial displacement following a needling procedure such as a core biopsy or fine needle aspiration. Epithelium can be displaced into the biopsy site, needle tract, lymphatic channels, or into axillary lymph nodes. [52] [53] [54] Nagi et al 55 evaluated epithelial displacement according to lesion type and found that epithelial displacement was identified in 50 of 53 (94.3%) papillary lesions, regardless of the type of needling procedure. This included a spectrum of lesions ranging from intraductal papilloma to invasive papillary carcinoma. Recognition of this phenomenon is particularly important to prevent misinterpretation. When epithelium has been mechanically transported to a lymph node, there are morphologic features that aid in recognizing its true character. In favor of benign mechanical transport are altered red blood cells and an inflammatory response usually consisting of hemosiderin-laden macrophages surrounding small clusters of epithelial cells. 54 Bleiweiss et al 56 recently found discordant immunohistochemical staining for HER2/neu and estrogen receptor (ER), combined with histologic characteristics, to be useful in identifying iatrogenic displacement and transport of benign epithelial cells to sentinel lymph nodes. however, the number of cases with atypia on excision was not specified. wAn unspecified number include cytologic diagnosis. zUpgrade to malignant: 12% of 11G; 30% of fine needle aspiration, 35% of 14G. y20 patients had excision at a median of 5 wk. Five patients had excision at a later date due to mammographic or clinical change. J2 patients were lost to follow-up. N indicates number of patients; NS, not specified.
CORE NEEDLE BIOPSY AND PAPILLARY LESIONS
The finding of a papillary lesion in a core biopsy of breast is relatively infrequent with recent series showing an incidence ranging from 0.73% 57 to 4%. 58 Core needle biopsy specimens are best interpreted with radiologic correlation to ensure that the targeted lesion has been adequately sampled. There is ongoing controversy regarding the management of benign papillary lesions when found on core biopsy. Although most authorities recommend excision of a papillary lesion with atypia as a more advanced lesion (DCIS or invasive carcinoma) is seen in the excisional biopsy in up to 75% of cases, [59] [60] [61] [62] [63] the management of a benign papillary lesion without atypia is less clear-cut. Table 1 summarizes a number of series that have evaluated the outcome in patients after a diagnosis of a benign papillary lesion on core biopsy. Definite conclusions cannot be derived from these studies as they are largely retrospective, include both symptomatic and screening populations, have limited follow-up and include a relatively small number of cases. Also, variations in terminologies add to the difficulty in their interpretation.
The main rationale for excising benign papillary lesions diagnosed on core biopsy is sampling error. The presence of ADH or DCIS within intraductal papillomas can be focal, thus easily missed on core biopsy; although, this risk is decreased with taking a greater number of cores or using larger gauge needles. Still there remains the fact that papillary lesions are diagnostically challenging, particularly on core biopsies and the pathologist's uncertainty is not an insignificant indication for excision. For these reasons, we favor that most benign papillary lesions diagnosed on core biopsy require excision and that radiologic follow-up be reserved for those cases where the lesion was an incidental finding on core or has been completely excised by the core biopsy process; radiologic-pathologic concordance is a prerequisite for such conservative management and any discordance between these two modalities should prompt excision.
THE USE OF IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF PAPILLARY LESIONS
Evaluation of papillary lesions is based primarily on morphologic features. Immunohistochemistry should, therefore, be reserved as an adjunct to diagnosis. Nevertheless, immunohistochemistry may be useful in the evaluation of papillary lesions, both on core needle biopsy and excision biopsy ( Table 2) . We find the combination of diffuse ER positivity, with absence of high molecular weight cytokeratin staining to be the most useful adjunctive test in discriminating ADH/low-grade DCIS within a papilloma from florid hyperplasia of usual type within a papilloma (Figs. 11A-D) .
The absence of myoepithelial markers within an intracystic papillary carcinoma (encapsulated papillary carcinoma) will aid in making this diagnosis. But myoepithelial markers will fail to assist in evaluating stromal invasion in intracystic papillary carcinoma (encapsulated papillary carcinoma) as discussed previously. 40 Other authors have shown utility for CD44 70 and cyclin D1 71 in differentiating benign from malignant papillary lesions; we do not use these markers in our practice.
In summary, the morphologic features remain the most important element in evaluating papillary lesions. This involves assessment of the epithelial component along with the presence or absence of myoepithelial cells, as summarized in the algorithm in Figure 12 . 
